{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:37:35Z","timestamp":1790519855202,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA-16359"],"award-info":[{"award-number":["CA-16359"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA196530"],"award-info":[{"award-number":["P50CA196530"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA126801"],"award-info":[{"award-number":["R01-CA126801"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001238","name":"Merck Company Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010900","name":"Yale Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015170","name":"Yale SPORE in Lung Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jtho.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T12:15:26Z","timestamp":1550060126000},"page":"1046-1060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras\/p53-Driven Lung Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Jong Woo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Jin","family":"Eoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kaftan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vali","family":"Papadimitrakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Seok","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2019.02.004_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2019.02.004_bib2","unstructured":"Howlader N NA, Krapcho M, Miller D, et\u00a0al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD. https:\/\/seer.cancer.gov\/csr\/1975_2014\/, based on November 2016 SEER data submission, posted to the SEER web site, April\u00a02017."},{"key":"10.1016\/j.jtho.2019.02.004_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/14728222.2014.1000304","article-title":"The potential of targeting Ras proteins in lung cancer","volume":"19","author":"McCormick","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jtho.2019.02.004_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00109-016-1382-7","article-title":"K-Ras protein as a drug target","volume":"94","author":"McCormick","year":"2016","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.jtho.2019.02.004_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2019.02.004_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non\u2013small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2019.02.004_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2018.05.001","article-title":"KRAS: reasons for optimism in lung cancer","volume":"99","author":"Lindsay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2019.02.004_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11864-018-0557-6","article-title":"Management of KRAS-mutant non\u2013small cell lung cancer in the era of precision medicine","volume":"19","author":"Aredo","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtho.2019.02.004_bib9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.02.004_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2019.02.004_bib11","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1158\/1078-0432.CCR-13-2365","article-title":"Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers","volume":"20","author":"Okumura","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.02.004_bib12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/annonc\/mdv072","article-title":"A\u00a0randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non\u2013small-cell lung cancer (NSCLC)dagger","volume":"26","author":"Blumenschein","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.02.004_bib13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/JTO.0b013e3181e8b3a3","article-title":"A\u00a0phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non\u2013small cell lung cancer who have failed one or two prior chemotherapeutic regimens","volume":"5","author":"Hainsworth","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.02.004_bib14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2015.12.010","volume":"17","author":"Janne","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2019.02.004_bib15","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"Janne","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2019.02.004_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.02.004_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti\u2013PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2019.02.004_bib18","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non\u2013small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2019.02.004_bib19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2019.02.004_bib20","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non\u2013small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2019.02.004_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non\u2013small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.02.004_bib22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","article-title":"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2019.02.004_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non\u2013small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2019.02.004_bib24","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nprot.2009.95","article-title":"Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase","volume":"4","author":"DuPage","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jtho.2019.02.004_bib25","article-title":"A\u00a0novel small-molecule inhibitor targeting CREB-CBP complex possesses anti-cancer effects along with cell cycle regulation, autophagy suppression and endoplasmic reticulum stress","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2019.02.004_bib26","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","article-title":"PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity","volume":"20","author":"Gato-Canas","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2019.02.004_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.02.004_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/annonc\/mdw008","article-title":"Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer","volume":"27","author":"Carter","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.02.004_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non\u2013small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"Janne","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.02.004_bib30","first-page":"27","article-title":"A\u00a0simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J\u00a0Basic Clin Pharm"},{"key":"10.1016\/j.jtho.2019.02.004_bib31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/2159-8290.CD-15-1377","article-title":"Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS-mutant lung cancer","volume":"6","author":"Kitai","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.02.004_bib32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature18600","article-title":"A\u00a0combinatorial strategy for treating KRAS-mutant lung cancer","volume":"534","author":"Manchado","year":"2016","journal-title":"Nature"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2019.02.004_bib33","first-page":"mdy208.003","article-title":"LBA-004 Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer","volume":"29","author":"Bendell","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.02.004_bib34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2019.02.004_bib35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2019.02.004_bib36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2019.02.004_bib37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.02.004_bib38","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti\u2013PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2019.02.004_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.jtho.2019.02.004_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2019.02.004_bib41","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/eji.201040895","article-title":"The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity","volume":"40","author":"Youn","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jtho.2019.02.004_bib42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2019.02.004_bib43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.02.004_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00262-005-0048-z","article-title":"Role of immature myeloid cells in mechanisms of immune evasion\u00a0in\u00a0cancer","volume":"55","author":"Kusmartsev","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2019.02.004_bib45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/sj.onc.1209237","article-title":"K-ras activation generates an inflammatory response in lung tumors","volume":"25","author":"Ji","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2019.02.004_bib46","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1158\/0008-5472.CAN-16-1308","article-title":"Trametinib drives T-cell\u2013dependent control of KRAS-mutated tumors by inhibiting pathological myelopoiesis","volume":"76","author":"Allegrezza","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2019.02.004_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2019.02.004_bib48","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1038\/srep13650","article-title":"IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway","volume":"5","author":"Sumida","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2019.02.004_bib49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641930111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641930111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:39:04Z","timestamp":1761561544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641930111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S155608641930111X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2019.02.004","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras\/p53-Driven Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}